Lifeboat Foundation

The potential threat of biological warfare with a specific agent is proportional to the susceptibility of the population to that agent. Preventing disease after exposure to a biological agent is partially a function of the immunity of the exposed individual. The only available countermeasure that can provide immediate immunity against a biological agent is passive antibody. Unlike vaccines, which require time to induce protective immunity and depend on the host’s ability to mount an immune response, passive antibody can theoretically confer protection regardless of the immune status of the host. Passive antibody therapy has substantial advantages over antimicrobial agents and other measures for postexposure prophylaxis, including low toxicity and high specific activity. Specific antibodies are active against the major agents of bioterrorism, including anthrax, smallpox, botulinum toxin, tularemia, and plague. This article proposes a biological defense initiative based on developing, producing, and stockpiling specific antibody reagents that can be used to protect the population against biological warfare threats.

Defense strategies against biological weapons include such measures as enhanced epidemiologic surveillance, vaccination, and use of antimicrobial agents, with the important caveat that the final line of defense is the immune system of the exposed individual. The potential threat of biological warfare and bioterrorism is inversely proportional to the number of immune persons in the targeted population. Thus, biological agents are potential weapons only against populations with a substantial proportion of susceptible persons. For example, smallpox virus would not be considered a useful biological weapon against a population universally immunized with vaccinia.

Vaccination can reduce the susceptibility of a population against specific threats provided that a safe vaccine exists that can induce a protective response. Unfortunately, inducing a protective response by vaccination may take longer than the time between exposure and onset of disease. Moreover, many vaccines require multiple doses to achieve a protective immune response, which would limit their usefulness in an emergency vaccination program to provide rapid prophylaxis after an attack. In fact, not all vaccine recipients mount a protective response, even after receiving the recommended immunization schedule. Persons with impaired immunity are often unable to generate effective response to vaccination, and certain vaccines may be contraindicated for them.

Satellites are studying the impacts on pollution and night lighting of measures taken to slow the spread of COVID-19.

Circa 2019

The development of new so-called metamaterials could lead to dramatic advances in military technology, particularly the ability to hide from sensors—even the human eye. Metamaterials, engineered composites designed to manipulate the electromagnetic spectrum, could lead to “invisible” tanks and armored vehicles, submarines undetectable by sonar, and weapons with improved seekers and guidance systems.

The big caveat though is that metamaterials are currently pretty difficult to manufacture and are still years away from full-scale production.

Continue reading “How Metamaterials Could Lead to Invisible Tanks and Super-Stealthy Submarines” »

Scientists have discovered some of the largest bacteria-infecting virus out there.

The most common materials in the world, including plastic, steel, glass or wood have distinct molecular and chemical properties that give them intrinsic qualities, such as strength, flexibility or transparency. But an entirely different class of materials, called metamaterials, are coming onto the scene.

Artificially engineered, these materials have unique geometries and physical structures that can manipulate any mechanical or electromagnetic wave that passes through them. Metamaterials can perform a host of futuristic tricks; they can absorb sound waves to produce silence, bend light to create an invisibility cloak and dampen seismic waves to safeguard a building against an earthquake.

Metamaterial applications are numerous, but here are five of the coolest.

COVID-19 may be just the beginning of mass pandemics.

A Permaculture Perspective : A new docuemntary introducing permaculture: designing a world where and planet can thrive.

Vir Biotechnology, a San Francisco-based biotechnology firm, said Wednesday that laboratory testing showed two of its antibody drugs appeared to neutralize the coronavirus that causes Covid-19 and that it would pursue testing them in people.

The company said that human tests of the drugs could begin in three to five months, putting it roughly in line with two other efforts to produce anti-coronavirus antibodies. Regeneron, based in Tarrytown, N.Y., has said that its antibodies could enter trials by early summer — and that its treatment, if it proves effective, could be available for some uses in the fall. Eli Lilly, which is developing anti-SARS-CoV-2 antibodies with AbCellera, a Vancouver biotech, has said it hopes to begin human tests in four months.

“Stopping this disease will take a combination of prevention and treatment approaches,” Vir CEO George Scangos said in a statement. “At Vir, we are fortunate that our existing antibody platform gave us a running start against COVID-19, and we have the internal and partnered capabilities to work on multiple approaches.”

Topline : Thousands of at-home coronavirus antibody tests, used to detect whether someone has had and is potentially resistant to the virus, will be made available in the U.K. within days, a public health director has said, following calls for more frontline workers to be tested.